Galectin Therapeutics to Webcast Corporate Update Following Annual Meeting of Stockholders
May 15 2015 - 8:00AM
Galectin Therapeutics (Nasdaq:GALT) will webcast a
corporate update at 9:45 A.M. ET on Thursday, May 21, 2015,
immediately following the business portion of the Company's Annual
Meeting of Stockholders. Additionally, Peter Traber, M.D.,
president, chief executive officer and chief medical officer will
discuss the Company's pipeline of galectin inhibitor compounds and
progress in development of treatments for liver fibrosis and
cancer.
Following his presentation, Dr. Traber will answer questions
from shareholders present at the meeting. Shareholders not
attending the meeting may submit questions in advance for Dr.
Traber's consideration; questions should be submitted via email to
contact@galectintherapeutics.com no later than May 20, 2015.
The presentation will be webcast live over the internet and can
be accessed by logging on to the Galectin Therapeutics website at
www.galectintherapeutics.com and entering the password Galectin.
The presentation may also be heard via teleconference by dialing
(888) 887-4214 (within the United States) or (913) 643-0354
(outside the United States). The passcode for participants is
576978. Please log in approximately 10 minutes before the event to
ensure a timely connection.
The webcast will also be archived on the Company's website.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer
based on the Company's unique understanding of galectin proteins,
which are key mediators of biologic function. Galectin seeks to
leverage extensive scientific and development expertise as well as
established relationships with external sources to achieve
cost-effective and efficient development. The Company is pursuing a
development pathway to clinical enhancement and commercialization
for its lead compounds in liver fibrosis and cancer. Additional
information is available at www.galectintherapeutics.com.
CONTACT: Galectin Therapeutics Inc.
Peter G. Traber, M.D.
President, CEO & CMO
(678) 620-3186
ir@galectintherapeutics.com
LHA
Kim Golodetz
(212) 838-3777
kgolodetz@lhai.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Sep 2023 to Sep 2024